Please assess the completion status of the following clinical trial:

Trial Title: PRIME: Pilot Study Evaluating Percutaneous Vaccination of BCG for Bladder Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~The patient must:~* Be 18 years of age or older~* Be able to give informed consent~* Have newly diagnosed or recurrent multi-focal Ta, Large Ta, High Grade Ta, CIS or T1 Bladder Cancer~* Determined by treating urologist to be a good candidate for BCG Induction Therapy~* Have an adequate marrow function (defined as white blood cells greater than 1.5 x 103/µl (or 1,500 cells/mm3) and platelets greater than 150,000 cells/mm3; these results can be within last 60 days from the day of signing informed consent~Exclusion Criteria:~The patient cannot:~* Be less than18 years of age~* Unable to give informed consent~* Have a history of muscle invasive bladder cancer~* Be self-reported to be immune-compromised (HIV, chronic immunomodulators, chronic corticosteroids)~* Have a history of tuberculosis and/or received BCG Percutaneous Vaccination~* Pregnant or planning to become pregnant.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: t

Study Arms:
- non-muscle invasive bladder cancer (Type: EXPERIMENTAL): Every patient meeting eligibility criteria will receive a standard WHO adult potency Bacillus Calmette-Guerin (BCG) immunization (1cc/50mg live mycobacilli) in the right or left deltoid. Following a 19 - 31day wait period after BCG vaccination patients will then receive standard strength BCG intravesical therapy returning once a week for 6 consecutive weeks. Cystoscopy will be performed at 3 and 6 months.~Interventions: BCG immunization in deltoid and BCG intravesical therapy once a week for 6 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).